Table 1:
Patient number | HIV status | Age | Gender | ART Current ARVs (2 y of death) | CD4 counts (cells/mm) | Viral Load (copies/ml) | Years with HIV |
---|---|---|---|---|---|---|---|
1 | + | 49 | M | 3TC, ABC, KTA, RTV, TFV, TZV, ZDV | 273 | N.D. | 10 |
2 | + | 64 | M | DRV, EPZ, RTV | 299 | 40 | 18 |
3 | + | 60 | F | ATR | 398 | N.D. | 11 |
4 | + | 59 | M | 3TC, CBV, D4T, NVP, TRU | 158 | 50 | 13 |
5 | + | 71 | F | 3TC, ATV, KTA, RTV, TRU, ZDV | 403 | N.D. | 16 |
6 | + | 52 | M | RTV, SQV, TRU | 317 | 50 | 10 |
7 | + | 52 | M | RTV, SQV, TRU | 317 | N.D. | 12 |
8 | + | 54 | F | EFV, TRU | 317 | 500 | 14 |
9 | +HIVE | 5 | F | None | 7 | 750,000 | 5 |
10 | +HIVE | 36 | M | None | 12 | 1,250,000 | 3 |
11 | +HIVE | 45 | M | None | 24 | 850,000 | 2 |
12 | +HIVE | 48 | F | None | 6 | 980,000 | 5 |
13 | +HIVE | 51 | M | None | 17 | 1,800,000 | 4 |
14 | − | 42 | F | N.A. | N.A. | N.A. | N.A. |
15 | − | 69 | M | N.A. | N.A. | N.A. | N.A. |
16 | − | 38 | M | N.A. | N.A. | N.A. | N.A. |
17 | − | 51 | F | N.A. | N.A. | N.A. | N.A. |
18 | − | 54 | M | N.A. | N.A. | N.A. | N.A. |
19 | − | 66 | M | N.A. | N.A. | N.A. | N.A. |
20 | − | 74 | F | N.A. | N.A. | N.A. | N.A. |
Notes: M: male; F: Female; N.A.: not applicable; N.D.: not detected.
Anti-retrovirals: 3TC, lamivudine (Epivir); ABC, abacavir (Ziagen); ATV, atazanavir (Reyataz); CBV, zidovudine + lamivudine (Combivir); D4T, stavudine (Zerit; EFV, efavirenz (Sustiva); EPZ, ziagen + epivir (Epzicom); KTA, LPV/RTV; lopinavir/ritonavir (Kaletra); NVP, nevirapine (Viramune); RTV, ritonavir (Norvir); FTV, SQV2 or FTV; saquinavir-sgc (Fortovase); SQV, saquinavir (Invirase); TFV, PMPA; tenofivir DF (Viread); DRV, TMC-114, darunavir (Prezista); TRU, emtricitabine + tenofovir (Truvada); TZV, AZT + 3TC + abacavir; zidovudine + lamivudine + abacavir (Trizivir); VCV, vicriviroc; ZDV, AZT, zidovudine (Retrovir).